The Rise of Pharma-Digital Partnerships in Mental Health: From pilots to scale
Our new article explores how pharma and digital health companies combine pharmacotherapy with behavioural interventions – we are covering four recent examples of such partnerships to explore the developments in this area.
Read to learn more about:
- A 6-dimensional evaluation framework: strategy, behavioural design, access, clinical impact, data governance, integration and scale.
- How to avoid the four key challenges: regulatory uncertainty & reimbursement gap, privacy/interoperability, strategic misalignment and inequity.
- What recent partnerships are: adherence support, AI-enabled diagnosis support, schizophrenia DTx, and virtual PPD care.
- Next steps to align evidence, workflows, and benefit design.
Contact: Chareen Lim, Senior Vice President, Advisory Services, Healthcare (US)
